Gerrit Jan Weverling

7.1k citations

88 papers · 5.0k indexed · 1 hit paper · h-index 40

Co-authors: Joep M. A. Lange Jaap Goudsmit Suzanne Jurriaans Peter Reiss Ferdinand W N M Wit Hanneke Schuitemaker Roel A. Coutinho Jan W. Mulder
Topics: HIV Research and Treatment (32 papers)HIV/AIDS drug development and treatment (29 papers)HIV/AIDS Research and Interventions (20 papers)
Cited by: Virology Infectious Diseases Hepatology
Journals: Proceedings of the National Academy of Sciences The Lancet Journal of Clinical Oncology
Partner nations: Netherlands United States United Kingdom

In The Last Decade

Gerrit Jan Weverling

88 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study

2020 215 citations Gerrit Jan Weverling, Wouter Koudstaal et al. profile →

Peers

Countries citing papers authored by Gerrit Jan Weverling

Since Specialization

Citations

This map shows the geographic impact of Gerrit Jan Weverling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerrit Jan Weverling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerrit Jan Weverling more than expected).

Fields of papers citing papers by Gerrit Jan Weverling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerrit Jan Weverling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerrit Jan Weverling. The network helps show where Gerrit Jan Weverling may publish in the future.

Co-authorship network of co-authors of Gerrit Jan Weverling

This figure shows the co-authorship network connecting the top 25 collaborators of Gerrit Jan Weverling. A scholar is included among the top collaborators of Gerrit Jan Weverling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerrit Jan Weverling. Gerrit Jan Weverling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pre‐ and Postexposure Use of Human Monoclonal Antibody against H5N1 and H1N1 Influenza Virus in Mice: Viable Alternative to Oseltamivir 2009 ·The Journal of Infectious Diseases ·Wouter Koudstaal,Martin H. Koldijk,Just P. J. Brakenhoff,Lisette A. H. M. Cornelissen,Gerrit Jan Weverling,Robert H. Friesen,Jaap Goudsmit	39
2	Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: Impact of distinct additional adjuvants 2008 ·Vaccine ·Katarina Radošević,Ariane Rodrı́guez,Ratna Mintardjo,(unknown),Karin Lövgren Bengtsson,Catherine Thompson,Maria Zambon,Gerrit Jan Weverling,F. G. C. M. UytdeHaag,Jaap Goudsmit	44
3	Mitochondrial DNA and RNA Increase in Peripheral Blood Mononuclear Cells from HIV‐1–Infected Patients Randomized to Receive Stavudine‐Containing or Stavudine‐Sparing Combination Therapy 2005 ·The Journal of Infectious Diseases ·Miriam Casula,Gerrit Jan Weverling,Ferdinand W.N.M. Wit,(unknown),Michael Stek,Joep M. A. Lange,Peter Reiss	36
4	Long-term results of endoscopic drainage of common bile duct strictures in chronic pancreatitis 2005 ·European Journal of Gastroenterology & Hepatology ·Djuna L. Cahen,(unknown),(unknown),Erik A.J. Rauws,Gerrit Jan Weverling,K. Huibregtse,Marco J. Bruno	62
5	Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets 2004 ·The Lancet ·Jan ter Meulen,Alexander B. H. Bakker,Edward N. van den Brink,Gerrit Jan Weverling,B Martina,Bart L. Haagmans,Thijs Kuiken,John de Kruif,Wolfgang Preiser,Willy J. M. Spaan,Hans R. Gelderblom,Jaap Goudsmit,Albert D. M. E. Osterhaus	205
6	Compartmentalisation of cytokines and cytokine inhibitors in ventilator-associated pneumonia 2004 ·Intensive Care Medicine ·Julian Millo,Marcus J. Schultz,C. M. Williams,Gerrit Jan Weverling,(unknown),(unknown),Tom van der Poll,Christopher S. Garrard	47
7	TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen 2003 ·AIDS ·(unknown),Gerrit Jan Weverling,Monika Peeters,(unknown),(unknown),Aza Rakhmanova,Sven A. Danner,Suzanne Jurriaans,Jan M. Prins,Joep MA Lange	33
8	Alanine administration does not stimulate gluconeogenesis in preterm infants 2003 ·Metabolism ·Anne Van Kempen,Johannes A. Romijn,An F.C. Ruiter,Erik Endert,Gerrit Jan Weverling,(unknown),Hans P. Sauerwein	14
9	Vascular Endothelial Growth Factor Levels in Serum Do Not Increase Following HIV Type 1 and HHV8 Seroconversion and Lack Correlation with AIDS-Related Kaposi's Sarcoma 2002 ·AIDS Research and Human Retroviruses ·Neil Renwick,Gerrit Jan Weverling,(unknown),Margreet Bakker,Thomas F. Schulz,Jaap Goudsmit	6
10	A survey of infectious agents as risk factors for primary sclerosing cholangitis: are Chlamydia species involved? 2002 ·European Journal of Gastroenterology & Hepatology ·Cyriel Y. Ponsioen,(unknown),Fiebo J.W. ten Kate,Gerrit Jan Weverling,Guido N.J. Tytgat,Yvonne Pannekoek,(unknown)	24
11	CC Chemokine Receptor 5 Δ32 and CC Chemokine Receptor 2 64I Polymorphisms Do Not Influence the Virologic and Immunologic Response to Antiretroviral Combination Therapy in Human Immunodeficiency Virus Type 1–Infected Patients 2002 ·The Journal of Infectious Diseases ·Ferdinand W.N.M. Wit,Ronald P. van Rij,Gerrit Jan Weverling,Joep M. A. Lange,Hanneke Schuitemaker	26
12	Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains 2001 ·AIDS ·Jaap Goudsmit,Gerrit Jan Weverling,Lia van der Hoek,Anthony de Ronde,Frank Miedema,Roel A. Coutinho,Joep M. A. Lange,Maarten C. Boerlijst	23
13	The ADAM study continued: maintenance therapy after 50 weeks of induction therapy 2001 ·AIDS ·Monique H. Reijers,Gerrit Jan Weverling,Suzanne Jurriaans,Marijke Roos,Ferdinand W N M Wit,Hugo M. Weigel,Reinier W. ten Kate,Jan W. Mulder,Clemens Richter,(unknown),Herman G. Sprenger,Richard M. W. Hoetelmans,Hanneke Schuitemaker,Joep M. A. Lange	5
14	Kaposi's sarcoma and human herpesvirus 8 infection do not protect HIV-1 infected homosexual men from AIDS dementia complex 2001 ·AIDS ·Neil Renwick,Gerrit Jan Weverling,Teysir Halaby,Peter Portegies,Margreet Bakker,Thomas F. Schulz,Jaap Goudsmit	3
15	Risk Factors for Hepatotoxicity in HIV-1--Infected Patients Receiving Ritonavir and Saquinavir with or without Stavudine 2000 ·Clinical Infectious Diseases ·Elizabeth H. Gisolf,Christa Dreezen,S. A. Danner,(unknown),Gerrit Jan Weverling,(unknown)	75
16	Toxicity and drug exposure in a quadruple drug regimen in HIV–1 infected patients participating in the ADAM study 2000 ·AIDS ·Monique H. Reijers,Hugo M. Weigel,Augustinus A. M. Hart,Reinier W. ten Kate,Jan W. Mulder,Peter Reiss,Hanneke Schuitemaker,Richard M. W. Hoetelmans,Gerrit Jan Weverling,Joep M. A. Lange	51
17	Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir 2000 ·AIDS ·Rieneke M. E. van Praag,Gerrit Jan Weverling,Peter Portegies,Suzanne Jurriaans,Xiao‐Jian Zhou,(unknown),Jean‐Pierre Sommadossi,David M. Burger,Joep M. A. Lange,Richard M. W. Hoetelmans,Jan M. Prins	82
18	Outcome and Predictors of Failure of Highly Active Antiretroviral Therapy: One‐Year Follow‐Up of a Cohort of Human Immunodeficiency Virus Type 1–Infected Persons 1999 ·The Journal of Infectious Diseases ·Ferdinand W N M Wit,Remko van Leeuwen,Gerrit Jan Weverling,Suzanne Jurriaans,Klaas Nauta,Radjin Steingrover,(unknown),(unknown),David Fortuin,(unknown),Frank de Wolf,Peter Reiss,Sven A. Danner,Joep M. A. Lange	148
19	Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors 1997 ·Journal of the Neurological Sciences ·Elisabeth S. Louwerse,Caroline E. Visser,Patrick M. Bossuyt,Gerrit Jan Weverling	87
20	Mortality risk stratification in amyotrophic lateral sclerosis 1995 ·Journal of the Neurological Sciences ·Elisabeth S. Louwerse,Patrick M. Bossuyt,Gerrit Jan Weverling,J.M.B.V. de Jong	3

About Gerrit Jan Weverling

Gerrit Jan Weverling is a scholar working on Virology, Infectious Diseases and Epidemiology, having authored 88 papers that have together received 5.0k indexed citations. Recurring topics across this work include HIV Research and Treatment (32 papers), HIV/AIDS drug development and treatment (29 papers) and HIV/AIDS Research and Interventions (20 papers). The work is most often cited by research in Virology (1.6k citations), Infectious Diseases (2.5k citations) and Hepatology (426 citations). Gerrit Jan Weverling has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Joep M. A. Lange, Jaap Goudsmit, Suzanne Jurriaans, Peter Reiss, Ferdinand W N M Wit, Hanneke Schuitemaker, Roel A. Coutinho, Jan W. Mulder, Richard M. W. Hoetelmans and Ferdinand W.N.M. Wit. Their work appears in journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact